Thymosin beta 4 fragment 17-23 explained: what the seven-amino-acid LKKTETQ peptide is, how it compares to TB-500, and its research and legal status.
Thymosin beta 4 fragment 17-23 is a seven-amino-acid synthetic peptide that matches the actin-binding region of the full 43-amino-acid thymosin beta-4 protein. Its sequence, LKKTETQ, sits at positions 17 through 23 of the parent molecule, which is why labs often treat it as the smallest unit that still carries thymosin beta-4's core actin-binding activity. The peptide is sold as a research chemical only and is not approved by the FDA for human use in the United States.
What Is Thymosin Beta 4 Fragment 17-23?
Thymosin beta-4 is a small protein found in nearly every human cell, where it helps regulate the actin cytoskeleton. The 17-23 fragment isolates one short stretch of that protein instead of using the whole chain.
- Length: seven amino acids
- Sequence: LKKTETQ (lysine-leucine-leucine-threonine-glutamate-threonine-glutamine)
- Position: residues 17 to 23 of full-length thymosin beta-4
- Primary studied function: binding to monomeric G-actin
- Typical supplied form: lyophilized powder, frequently the N-acetylated peptide
Short peptides are generally cheaper to synthesize, easier to ship, and simpler to store than full-length proteins. That practical advantage is one reason the fragment appears in research catalogs next to the complete molecule.
Thymosin Beta 4 Fragment 17-23 vs Thymosin Beta 4 and TB-500
Vendors use these three names loosely, so it helps to separate them by sequence rather than by marketing label. TB-500 and thymosin beta 4 fragment 17-23 are not interchangeable names for the same molecule.
| Feature | Fragment 17-23 | TB-500 (as sold) | Full-length thymosin beta-4 |
|---|---|---|---|
| Amino acid length | 7 | Usually labeled as 43; labels vary | 43 |
| Sequence | LKKTETQ, residues 17-23 | Often listed as the full thymosin beta-4 chain | Full 43-residue chain |
| Actin-binding motif | Is the motif | Contains the motif | Contains the motif |
| Typical form | Lyophilized powder | Lyophilized powder | Synthetic or recombinant protein |
| FDA status | Not approved for human use | Not approved for human use | Not approved for human use |
The phrasing "tb-500 thymosin beta 4 fragment 17-23" shows up in listings where sellers blend two different naming systems. Always check the certificate of analysis and the stated molecular weight before assuming two products are equivalent.
Why the 17-23 Sequence Matters in the Lab
Actin is the most abundant protein in most cells, and its assembly and disassembly drive cell movement, shape changes, and tissue closure. The 17-23 sequence binds G-actin and helps regulate that process.
Laboratory work on this region has examined cell migration, blood vessel formation, and tissue repair in cell cultures and animal models. Those models generate hypotheses, but they do not prove that a peptide treats disease in people.
Scientists also compare thymosin beta 4 fragment 17-23 vs thymosin beta-4 as a whole to see whether a short actin-binding motif can reproduce biological effects on its own. Results have been mixed, and the full protein carries functions that the seven-residue fragment does not.
Where the Fragment Appears in Research
Corneal and eye surface studies
Much of the early thymosin beta-4 literature focused on the cornea, where the protein is naturally abundant. Scientists working with thymosin beta 4 dry eye models have tested whether actin-binding peptides support cell migration across the corneal surface. Human clinical data remain limited.
Wound healing and tissue repair
Animal studies have looked at the peptide in skin, tendon, and cardiac repair models. Reviews of this work describe promising but preliminary signals rather than established treatments.
Hair follicle research
Some cell and animal studies on thymosin beta 4 hair growth have examined follicle stem cell activation. Human evidence for hair regrowth is thin, and no regulatory agency has approved the peptide for that purpose.
Inflammation and infection research
During the pandemic, investigators explored thymosin beta 4 covid research because of the peptide's role in immune cell movement and tissue repair. Published reviews describe early-stage and sometimes conflicting findings, not a proven therapy.
Forms, Storage, and Handling
Most catalog products ship as lyophilized powder. The common salt form is thymosin beta 4 acetate, because acetate improves stability during synthesis and shipping.
Typical vendor guidance is to store powder at -20 degrees Celsius or colder, avoid repeated freeze-thaw cycles, and protect reconstituted solutions from light. Follow the specific instructions that come with the product you purchase.
Safety, Legal Status, and Buyer Checklist
Thymosin beta 4 fragment 17-23 is not FDA-approved, not a dietary supplement, and not a prescription drug. In the United States it is sold as a research chemical labeled for laboratory use only, and selling it for human consumption is not permitted.
Anyone considering a thymosin beta 4 injection bought online should know that research-grade peptides are not manufactured under pharmaceutical sterility standards. Purity varies by vendor, human dosing is not established, and published human data on thymosin beta 4 injection dosage is scarce. Reported side effects in human studies of the full peptide have generally been mild, but those trials used pharmaceutical-grade material under medical supervision.
Before using any peptide, talk with a licensed healthcare professional. Self-injecting unapproved products carries real risks, including infection, allergic reaction, and contamination.
- Request a third-party certificate of analysis showing HPLC purity and mass spectrometry data.
- Confirm that the stated sequence and molecular weight match the fragment you actually want.
- Look for endotoxin testing if the material is intended for cell culture work.
- Be skeptical of any vendor that advertises human dosing or promises specific health outcomes.
Thymosin beta 4 fragment 17-23 is a seven-amino-acid piece of a larger protein, not a stand-alone therapy. Treat vendor claims about it as marketing until independent, peer-reviewed human data say otherwise.
Frequently Asked Questions
Is thymosin beta 4 fragment 17-23 the same as TB-500?
No. Thymosin beta 4 fragment 17-23 is a seven-amino-acid sequence called LKKTETQ, while products sold as TB-500 are typically labeled as the full 43-amino-acid thymosin beta-4 peptide. Labeling in this market is inconsistent, so buyers should read the certificate of analysis and compare the stated sequence and molecular weight before treating two products as identical.
Is thymosin beta 4 fragment 17-23 FDA approved?
No. Thymosin beta 4 fragment 17-23 is not FDA-approved for human use and is sold strictly as a research chemical for laboratory work. Injecting research-grade peptides purchased online carries risks such as infection, contamination, and unknown dosing. Anyone considering it for a health condition should consult a licensed healthcare professional instead.
What is thymosin beta 4 fragment 17-23 used for in research?
Labs use the fragment to study actin binding, cell migration, and tissue repair in cell cultures and animal models. Some of that work overlaps with corneal, wound-healing, and hair follicle research. These findings are preliminary and do not establish that the peptide prevents or treats any human disease.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.